
price close busi august
biotech discov
invent manufactur commerci medicin
treat seriou diseas
us eylea miss investor seem
focus pipelin
us eylea miss inventori rebat increas due lucenti competit
us eylea revenu miss consensu estim
due inventori drawdown potenti hangov concern inflamm
confin specif batch syring eylea continu expect posit fda
respons august sbla dose interv wet howev
brolucizumab threat novarti port deliveri system pd format
lucenti genentech still potenti threat wet space
manag indic preclin success higher dose
eylea could extend half-lif dose interv expect advanc
higher dose clinic continu believ eylea face meaning
competit headwind evidenc increas discount us eylea sale
make vast major revenu time come
launch key unlock full valu
world-wide net sale dupix beat consensu slightli
miss estim sanofi previous report week inventori build
account sale sanofi believ us ex-u demand
grew strongli note inventori midpoint rang
therefor expect signific inventori build balanc
continu expect posit fda respons sbla asthma adult/adolesc
patient octob sanofi hope broad label dupix us
asthma eosinophil count despit better efficaci among high count patient
suspect fda may specif high eosinophil count dupix administ
home edg xolair could increas uptak reiter view
dupix like see uptak acceler pediatr atop dermat
indic launch around make bulk opportun
initi phase studi younger pediatr sever atop dermat patient
month year old close monitor
expect cemiplimab cscc approv eye lung cancer readout
continu expect posit fda decis octob cemiplimab bla
advanc cutan squamou cell carcinoma cscc note third
market term inhibitor also need differenti vs merck
bristol non-smal cell lung cancer like requir surviv advantag
requir signific time clinic trial standpoint report increas
enrol size on-going phase non-smal cell lung cancer nsclc
monotherapi trial mainli increas studi power continu monitor
trial expect data readout given keytruda current
indic nsclc posit readout would signific inflect point
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
maintain hold rais pt multipl expect posit
maintain hold rate rais pt multipl near-term posit
catalyst expect like dupix approv uncontrol persist asthma
cemiplimab approv cscc octob believ dupix ramp
somewhat asthma signific uptak depend allergist expand
prescrib beyond patient suitabl xolair doctor switch patient
xolair dupix also remain concern lack eylea guidanc
potenti competit roch genentech novarti wet dme
market threaten product gener major regn revenu
hold unchang target price august
figur actual vs consensu cg estim
hold unchang target price august
regeneron actual vs estim except per actualconsensuscanaccordconsensuscanaccordeylea- eylea- sanofi collabor bayer collabor net product total sg oper net incom net incom ep fulli non- ep fulli dupix dupix ex estimatesactu vs full year estim except per share newoldtot net product us sanofi collabor bayer collabor sg net incom net incom ep ep canaccord guidanceoldchang non- billionyesnon- billionyescap millionyescash tax non- pre-tax reimburs milliony figur upcom expect catalyst
hold unchang target price august
aug aug oct oct antibodiesregulatori investig new drug applic ind antibodyfda regulatori submiss npdr non-dm patientsregulatori sbla expand indic adolesc year age atop dermatitisfda decis uncontrol persist asthmadata ph one-year data panorama trial npdr innon-dm patientsfda decis sbla use ph studi osteoarthritisfda decis dose interv wet amdfda decis bla advanc csccdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat figur valuat dcf
hold unchang target price august
regeneron dcf valuat free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate regeneron
hold unchang target price august
hold unchang target price august
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price august
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand
